

TABLE OF CONTENTS

<i>Welcome and Current Status of CPDD</i> L.S.Harris	1
<i>The National Institute on Drug Abuse 1991: New Faces, Responsibilities, and Opportunities</i> C. R. Schuster	3
<i>Biomedical Research and Scientific Citizenship: The Price of Progress</i> F. K. Goodwin	10
<i>Introduction of the Nathan B. Eddy Award Co-Recipients</i> E.L.Way	18
<i>Opioid Pharmacology a' la mode</i> A. E. Takemori	21
<i>Chemical Tools in Opioid Research</i> P. S. Portoghese	27

SYMPOSIUM I

UPDATE ON OPIOIDS: FROM MOLECULES TO THE CLINIC

<i>Recent Studies on a Mu-Opioid Binding Protein Purified from Bovine Striatal Membranes</i> T. L. Gioannini, Y. H. Yao, J. M. Hiller and E. J. Simon	34
<i>Effects of Endogenous Calcium Regulating Peptides on Opiate Actions</i> S. L. Welch, F. Smith, M. Saxen and W. L Dewey.	39
<i>Effects of Opiates, Opioid Antagonists and Cocaine on the Endogenous Opioid System: Clinical and Laboratory Studies</i> M.J.Kreek	44

SYMPOSIUM II

A CELEBRATION of the GOLDEN ANNIVERSARY of INTRAMURAL MEDICINAL CHEMISTRY RESEARCH in the NIDDK: 1941-1991 in BETHESDA: A CONTINUING INTERRELATIONSHIP with the CPDD THROUGH NEUROSCIENCE

<i>The Continuing Interrelationship of CPDD and NIDDK</i> A. E. Jacobson and K. C. Rice	49
<i>Potent Analgesia, Respiratory Depression, Dependence, Abuse Liability - Clue to Separability</i> A. H. Newman, K. C. Rice and A. E. Jacobson	54
<i>Leads to Current Therapy, Co Opioid Receptor Subtypes and to Sigma Receptors</i> E.L.May	59
<i>State-of-the-Art Analgesics from the Agonist-Antagonist Concept</i> S. Archer	71
<i>Novel Kappa Opioid Receptor and Sigma Receptor Ligands</i> B. de Costa, R. B. Rothman, W. D. Bowen, L. Radesca L. Band, A. Reid, L. D. Paolo, J. M. Walker, A. E. Jacobson and K. C. Rice	76
<i>Three Generations of Electrophilic Affinity Ligands for the Phencyclidine Binding Sites</i> A. E. Jacobson, J. T. M. Linders, K. C. Rice, J. A. Monn, M. V. Mattson and C. George	81
<i>The Cannabinoid Receptor - Pharmacologic Identification, Anatomical Localization and Cloning</i> M. R. Johnson, K. C. Rice, A. Howlett, L. S. Melvin and M. Herkenham	86
<i>Opiate Total Synthesis and Contemporary NIDDK Analgesic Research - Natural and Unnatural Ligands for Computed Tomography Imaging of Receptors in Conscious Humans. Implications for Future Advances in the Neurosciences</i> K.C.Rice	91
<i>Overview of opioid Medicinal Chemistry</i> J. W. Lewis	96

SYMPOSIUM III

DSM CONTROVERSY

<i>DSM-IV Substance Use Disorders: The View from DSM-IIIR</i> B. J. Rounsaville	101
--	-----

SYMPOSIUM IV

PERINATAL SUBSTANCE ABUSE

<i>Effects of Drugs of Abuse and Treatment Agents in Women</i> M.J.Kreek	106
<i>Cardiovascular Effects of Cocaine in Pregnancy and on the Fetus</i> J. R. Woods. Jr.	111

Neurological Outcome in Infants Exposed to Stimulants in the Perinatal Period S.D. Dixon	116
Effects of Cocaine and Other Drugs on the Infant C.D. Coles	121
Fetal Alcohol Syndrome: Early and Long-Term Consequences A. P. Streissguth	126

SYMPOSIUM V

SEROTONIN AND DRUGS OF ABUSE

Hallucinogens and Serotonergic Mechanisms R. A. Glennon, M. Tettler and E. Sanders-Bush	131
Self Administration of Stimulants and Serotonergic Systems D. S. Roberts	136
Serotonin and Alcohol Drinking E. M. Sellers, G. A. Higgins, D. M. Tompkins and M. K. Romach	141
Pharmacotherapy of Substance Abuse with Serotonergic Drugs T.R.Kosten	146

SYMPOSIUM VI

BEHAVIORAL STRATEGIES FOR THE EVALUATION OF NEW PHARMACOTHERAPIES FOR DRUG ABUSE TREATMENT

Behavioral Strategies for the Evaluation of New Pharmacotherapies for Drug Abuse Treatment N.K.Mello	150
Assessment of New Medications for Stimulant Abuse Treatment W. L. Woolverton and M. S. Kleven	155
Preclinical Methods for the Development of Pharmacotherapies for Cocaine Abuse R. L. Balster, R.S. Mansbach, L. Gold and L.S. Harris .	160
A Laboratory Model for Evaluating Potential Treatment Medications in Humans M. W. Fischman and R. W. Foltin	165
Clinical Parallels of Chronic Drug Self-Administration Models for Treatment Evaluation J. H. Mendelson and N. K. Mello	170
Use of Cocaine-Discrimination Techniques for Preclinical Evaluation of Candidate Therapeutics for Cocaine Dependence R. D. Spealman	175
The Use of Human Drug Discrimination Studies in Medication Development C. E. Johanson	180

SYMPOSIUM VII

NOVEL STRATEGIES FOR COCAINE DEPENDENCE

Cocaine-Antagonist Effects of Limited-Efficacy D. Agonists
J. Bergman and S. Rosenzweig-Lipson 185

Potential Effects of Benzodiazepines on Cocaine Reinforcement in Rats
N. E. Goeders 190

Effects of Magnesium on Cocaine-Reinforced Responding in Mice, Rats and Squirrel Monkeys
K.M.Kantak 195

Access Schedules of Oral Cocaine and Ethanol in Rats
H. Marcucella, A. Liguori, P. Steffen, S. Gutowski
and T. O'Connor 200

ORAL COMMUNICATIONS I

BIOCHEMICAL AND BEHAVIORAL PHARMACOLOGY

Effects of Cannabinoids on Synaptosomal Transmembrane Potential
A. S. Bloom and M. Swiderski 205

Comparison of Lipophilicity and Antinociceptive Effect of Intrathecally Administered Cannabinoids
P. B. Smith, A. H. Lichtman and B. R. Martin 206

Delta⁹-THC-Induced Antinociception is Mediated by Spinal α_2 Noradrenergic Receptors
A. H. Lichtman and B. R. Martin 207

[3H]PCP Covalent Binding to liver Microsomal Proteins is Significantly Affected by the Length of Chronic Dosing
S. M. Owens, M. Gunnell and M. J. J. Ronis 208

Dependence on Dizocilpine (MK-801) in Rats
W. D. Wessinger 209

Dextrorphan (DO) but not Dextromethorphan (DM) Induces PCP-Like Behavior in Rats
J. I. Szekely, L. G. Sharpe and J. H. Jaffe 210

The 5-HT₃ Antagonist MDL 72222 Selectively Blocks the Discriminative Stimulus Effects of Ethanol in Rats
K.A.Grant 211

Self-injection, Discrimination and Tolerance with Zolpidem in Baboons
R. R. Griffiths, C. A. Sannerud, N. A. Ator
and J. V. Brady 212

Chronic Administration of the Imidazopyridines Zolpidem and Alpidem, Does Not Produce Physical Dependence in Mice
D. J. Sanger, G. Perrault, E. Morel and B. Zivkovic 213

Effects of Benzodiazepines on Memory in Monkeys
J.M.Moerschbaecher 214

ORAL COMMUNICATIONS II

CLINICAL BEHAVIORAL PHARMACOLOGY

Effects of Pentazocine, Nalbuphine and Buprenorphine in Humans Trained to Discriminate among Saline, Hydromorphone and Butorphanol
G. E. Bigelow, K. L. Preston and I. A. Liebson 215

Subjective and Behavioral Responses to Intravenous Fentanyl in Healthy Volunteers
J. P. Zacny, J. L. Lichtor, J. G. Zaragoza
and H. de Wit 216

Effects Multiple Doses of Smoked Cocaine-Base
D. Hatsukami, P. Pentel, R. Nelson and J. Glass 217

Behavioral Effects of Ethanol and Marijuana, Alone and in Combination with Cocaine in Humans
R. W. Foltin, M. W. Fischman and T. H. Kelly 218

Clinical Effects of Daily Methamphetamine Administration
M. Perez-Reyes, W. R. White, S. A. McDonald,
R. E. Hicks, A. R. Jeffcoat, J. A. Hill
and C.E.Cook 219

Effects of Acute Cocaine on Cerebral Glucose Utilization in Human Polydrug Abusers: Relations between Regional Metabolism and Subjective Responses
E. D. London, J. M. Stapleton, B. C. K. Yung,
R.L. Phillips, M. J. Morgan, N. G. Cascella,
D. F. Wong and J. H. Jaffe 220

Caffeine Drug Discrimination in Humans: Effects of Theophylline, Methylphenidate and Bupirone
A. H. Oliveto, W. K. Bickel, J. R. Hughes,
S. Y. Terry and S. T. Higgins 221

Profile of Behavioral Effects of the Benzodiazepine, Triazolam, as Compared to Ethanol
J. D. Roache, R. H. Bennett, D. R. Cherek,
K. A. Cowan and R. Spiga 222

Ethanol Preload Increases Ethanol Preference in Normal Social Drinkers
H. de Wit and M. A. Chutuape 223

Chronic Tolerance to Cardiovascular, Subjective, and Behavioral Effects of Nicotine in Humans
K. A. Perkins, J. E. Grobe, L. H. Epstein,
R. L. Stiller, R. Solberg-Kassel and R. G. Jacob . . . 224

ORAL COMMUNICATIONS III

PSYCHIATRIC CO-MORBIDITY in COCAINE AND OPIATE ADDICTS

Substance Dependence Diagnosis Using DSM-III-R and DSM-IV Criteria for Cocaine Users
K. J. Bryant and B. Rounsaville 225

DSM-III-R Dependence Without Tolerance or Withdrawal
J. E. Helzer, L. B. Cottler, D. Mager,
E. L. Spitznagel and W. M. Compton, III. 226

Prevalence of Comorbidity Among Cocaine Users in Treatment B. E. Havassy and D. A. Wasserman	227
Psychiatric Histories among Drug Abusers: IVDU vs. Non-IVDD L. B. Cottler, W. B. Compton, III., D. Mager. G. A. Storch and J. Hudziak	228
Consistency in Measurement of Psychopathology D. L. Haller, J. S. Knisely and S. H. Schnoll	229
Psychiatry Comorbidity in Methadone Maintained Patients B. J. Mason, J. H. Kocsis, D. Melia, E. T. Khuri, R. B. Millman, J. Sweeney, A. Wells and M. J. Kreek . . .	230
Comparison of Antisocial Personality and Psychopathy in Opiate Addicts J. S. Cacciola, M. J. Rutherford and A. I. Alterman . . .	231
The Personality Dimensions of Male and Female Drug Abusers With and Without Antisocial Personality Disorder R. K. Brooner, P. T. Costa, L. J. Felch, E. E. Rousar, G. E. Bigelow and C. W. Schmidt	232
Vaitdity of the Drug Abuse Screening Test (DAST-10) in Inpatient Substance Abusers M. J. Bohn, T. F. Babor and H. R. Kranzler	233

ORAL COMMUNICATIONS IV

COCAINE RECEPTORS, DOPAMINE TRANSPORTERS, AND RELATED EVENTS

[¹²⁵I]RTI-55: A Potent Ligand for the Cocaine Receptor J. W. Boja, A. Patel, T. A. Kopajtic, W. M. Mitchell, F. I. Carroll, M. A. Rahman, P. Abraham, A. H. Lewin and M. J. Kuhar	234
Characterization and Localization of ³H-WIN 35,428 Binding Sites in Rabbit Brain V. J. Aloyo, A. L. Kirifides and J. A. Harvey	235
Imaging Probes for Cocaine Receptors in Human and Non-human Primate Brain B. K. Madras, M. J. Kaufman, R. D. Spealman, M. A. Fahey, J. Schumacher, O. Isacson, P. Meltzer, A. Liang, G. L. Brownell, A. L. Brownell and D. R. Elmaleh	236
Evidence for Multiple [3H]GBR12935 Binding Sites Associated with the Dopamine Transporter in Rat Striatal Membranes H. C. Akunne, B. R. de Costa, K. C. Rice and R. B. Rothman	237
Comparison of the Molecular Weight of the Dopamine Transporter in Rat Nucleus Accumbens and Striatum R. Lew, R. Vaughan, R. Simantov and M. J. Kuhar	238
Structure Activity Relationship of Dopamine Transporter Ligands M. F. Davies, H. O. Villar, P. A. Maguire and G.H.Loew	239
Differential Effects of Cocaine and Cocaethylene on Extracellular Dopamine and Serotonin in the Rat Striatum B. Lin, M. Y. T. Globus, M. D. Ginsberg, W. L. Hearn and D. C.Mash	240

Repeated and Chronic Cocaine Treatments Have Differential Effects on Serotonin and Dopamine Uptake in Rat Striatum and Nucleus Accumbens	
S. Izenwasser and B. M. Cox	241

Cocaine Sensitization is Associated with Modified Serotonin Function	
J. M. Paris, N. E. Goeders and K. A. Cunningham	242

Neurotransmitter Receptor-Effector Alterations in Rhesus Monkey Brain Following Repeated Cocaine Injections	
G. M. Farfel, M. S. Wainwright, H. I. Salti, M.S. Kleven, W. L. Woolverton, L. S. Seiden and B. D. Perry	243

ORAL COMMUNICATIONS V

CLINICAL PHARMACOLOGY

Pharmacologic and Behavioral Effects of High Doses of Intravenous Buprenorphine	
E. Cone, B. Holicky, W. Pickworth and R. E. Johnson	244

The Acute Effects of High Dose Buprenorphine in Non-Dependent Humans	
S. L. Walsh, K. L. Preston, M. L. Stitzer, G. E. Bigelow and I. A. Liebson	245

Comparison of Agonist and Antagonist Sensitivity in Opiate-Naive and Opiate-Experienced Humans	
S. J. Heishman, R. C. Taylor, A. Francis-Wood, C. Cohen and J. E. Henningfield	246

Human Pharmacology of the Opioid Antagonist, Nalmefene	
J. E. Henningfield, S. J. Heishman, L. M. Richards, H. Lee, P. J. Fudala and R. E. Johnson	247

Plasma Norharman (β-Carbolone) Levels are Significantly Higher in Alcoholics than in Non-alcoholics	
H. Rommelspacher and L. G. Schmidt	248

Pharmacokinetic Comparisons of Smoked and Intravenous Delta-Tetrahydrocannabinol (THC) in Humans Before and After Daily Smoking of Marijuana	
C. E. Cook, M. Perez-Reyes, A. R. Jeffcoat, B. Jeffcoat, B. M. Sadler, D. R. Brine, R. D. Voyksner, W. R. White and S. McDonald	249

Caffeine Intake as a Cause of Nicotine Withdrawal	
J. R. Hughes, A. H. Oliveto, S. Y. Terry, S.T. Higgins and W. K. Bickel	250

Termination of Normal Dietary Caffeine Produces Clinically Significant Withdrawal Symptoms	
K. Silverman, S. M. Evans, E. C. Strain and R. R. Griffiths	251

ORAL COMMUNICATIONS VI

OPIATE RECEPTORS AND LIGANDS: MOLECULAR STUDIES

Antisera Generated Against a Peptide Complementary to H- β -Endorphin Inhibit β -Endorphin Binding to Human U937 Cells
 N. Shahabi, K. Bost and B. Sharp 252

Comparison of μ -Opioid Binding in Intact Neuroblastoma Cells and in Broken Cell Preparations
 L. Toll 253

Opioid Receptor Subtype Selectivity of the Phenylmorphans and Analogs
 M. Froimowitz, C. Pick and G. W. Pasternak 254

*Effect of β -FNA Administration on *In Situ* μ Opioid Binding*
 T. J. Martin and J. E. Smith 255

Opioids Regulate hCG Release from Trophoblast Tissue of Term Human Placenta
 B. Cemerikic, J. Cheng, A. Agbas, D. Maulik and M. S. Ahmed 256

In Vivo Pharmacology of Potent, μ -Selective Opioids: Variations in Opioid Efficacy
 C. P. France, G. Winger, M. R. Seggel, K. C. Rice and J. H. Woods 257

Displacement of μ and δ Opioid Receptor Ligands by Morphine in Mouse and Rat Brain
 B. C. Yoburn and B. A. Billings 258

Lack of Antinociceptive Cross-Tolerance Between [D-Pen², D-PEN⁷]Enkephalin and [D-ALA²]Deltorphin II: Evidence for Delta Receptor Subtypes
 A. Mattia. T. Vanderah and F. Porreca 259

Characterization of [³H]DTG, [³H](+)-3-PPP and [³H](+)-Pentazocine Binding Sites in NB41A3 Neuroblastome, C6 Glioma, and NG108-15 Hybrid Cells: Further Evidence for Sigma Receptor Subtypes
 B. Vilner and W. D. Bowen 260

β -Endorphin Stimulates Opioid Receptor-G Protein Activation at μ and δ Receptors
 D. E. Selley and J. M. Bidlack 261

Opioid Enhancement of Enkephalin Release May Require Phosphatidylinositol-Derived Second Messengers
 A. R. Gintzler and H. Xu 262

The Effects of Chronic Administration of Morphine on the levels of Calcitonin Gene-Related Peptide (CGRP) in Brain Regions of the Rat
 S. P. Welch, P. P. Bass, K. G. Olson, A. R. Schatz and W. L. Dewey 263

Effects of Morphine Treatment on mRNA Levels of Pro-Opiomelanocortin and Proto-oncogene c-fos in a Neuroblastoma Cell
 S. L. Chang, L. Spriggs and J. E. Zadina 264

Excitatory Amino Acid Neurotransmitters and Morphine Withdrawal: Differential Effects of Central and Peripheral Kynurenic ACI Administration	
J. H. Krystal, K. Rasmussen and G. K. Aghajanian . . .	265

C-FOS Expression is Induced by Opioid Withdrawal and Blocked by NMDA Antagonists	
C. E. Inturrisi, M. Brodsky and K. Rasmussen	266

ORAL COMMUNICATIONS VII

GENETICS, FAMILY STUDIES and PERINATAL EFFECTS

Genetic Factors in Human Drug Abuse	
R. W. Pickens, D. S. Svikis and M. McGue	267

Risk for Alcoholism in Relatives of Drug Addicts	
L. Handelsman, M. Branchey, J. Silverman and L. Buydens-Branchey	268

Prolactin and Cortisol Levels After Acute Ethanol Challenge in Women With and Without a Family History of Alcoholism: A Pilot Study	
B. W. Lex, J. E. Ellingboe, S. K. Teoh, J. H. Mendelson and E. M. Rhoades	269

Improving Treatment Outcomes in Pregnant Opiate Addicts	
G. Chang, K. Carroll, H. M. Behr and T. R. Kosten . . .	270

Can a Weekly Support Group for Pregnant Addicts Improve Maternal and Fetal Outcome?	
D. S. Svikis, M. E. McCaul, T. Feng, T. B. R. Johnson and E. J. Stokes	271

Fetal Stress Associated With Cocaine Withdrawal	
J. T. Christmas, J. S. Knisely, S. H. Schnoll and S. Ruddy	272

A Comparison of the Antinociceptive Effects of Opioids in Neonatal and Adult Rats	
C. R. McLaughlin and W. L. Dewey	273

Effects of Early Postnatal Exposure to Morphine on Rat Pup Distress Vocalization and Analgesia	
G. A. Barr and S. Wang	274

Maternal and Fetal Plasma Disposition of Cocaine (C) in Near-term Macaque Monkeys	
M. G. Paule, J. R. Bailey, C. M. Fogle, M. P. Gillam, H. M. Duhart and W. Slikker, Jr.	275

Period-Specific Effects of Developmental Cocaine Exposure: Neuroanatomical Findings	
D. L. Dow-Edwards	276

ORAL COMMUNICATIONS VIII

PRECLINICAL BEHAVIORAL PHARMACOLOGY

Preclinical Strategies in the Development of Cocaine Abuse Pharmacotherapy	
R. S. Mansbach and R. L. Balster	277

Effects of Central Chlordiazepoxide Infusions on Intravenous Cocaine Self-Administration in Rats	
G. F. Guerin and N. E. Goeders	278
The Effects of Buspirone and Gepirone on Cocaine Self-Administration in Rhesus Monkeys	
L. H. Gold and R. L. Balster	279
Effects of Continuous Administration of the Monoamine Uptake Inhibitors, Fluoxetine, Sertraline, and Mazindol on Behavior Maintained by Cocaine or Food in Rhesus Monkeys	
W. L. Woolverton and M. S. Kleven	280
Mediation of A10 Somatodendritic Dopamine Release by Opioids and GABA	
M. A. Klitenick and P. W. Kalivas	281
Extracellular Acetylcholine and Dopamine in the Nucleus Accumbens following Morphine and Naloxone-Precipitated Withdrawal: Possible Role in Addiction	
P. Rada, G. P. Mark, E. Pothos and B. G. Hoebel	282
Interactions of Ibogaine With Morphine in Rats: Drug Self-Administration and In Vivo Microdialysis	
S. D. Glick, I. M. Maisonneuve, J. N. Carlson and R. W. Keller	283
Interactions of Ibogaine and D-amphetamine in Rats: Motor Behavior and In Vivo Microdialysis	
I. M. Maisonneuve and S. D. Glick	284
Ibogaine Alters Cocaine-Induced Biogenic Amine and Psychostimulant Dysfunction but not [³H]GBR-12935 Binding to the Dopamine Transporter Protein	
P. A. Broderick, F. T. Phelan and S. P. Berger	285

ORAL COMMUNICATIONS IX

PHYSIOLOGY AND PHARMACOLOGY

Nor-Binaltrophimine Interacts with Dynorphin-Induced Regulation of Morphine Effects on EEC and EEC Power Spectra	
N. C. Paquette and G. A. Young	286
EEC Changes with Acquisition of Morphine Self-Administration	
K. Grasing and H. Szeto	287
Cocaine-Induced Seizures are Inhibited by Serotonergic 5HT₂ and 5HT₃ Receptor Antagonists	
F. R. George and M. C. Ritz	288
Antidepressants Appear to Enhance Cocaine-Induced Seizures and Lethality	
M. C. Ritz and F. R. George	289
NMDA Modulators Protect Against Cocaine Convulsions Resistant to Other Anticonvulsants	
F. C. Tortella, R. J. Marley and J. M. Witkin	290
Cocaine has no Direct Vasoactive Effects	
S. Pal, D. Morley and A. A. Bove	291

Myocardial Damage Induced by Chronic Cocaine Administration in the Rat	
M. Maillet, G. Nahas, D. Chiarasini, M. Heller, H. Copin and C. Latour	292
Ethanol Vasoconstriction is Not Prevented by Diltiazem	
A. A. Bove, X.-Y. Zhang and D. Morley,	293
Low Doses of Ethanol Abolish Nitroprusside Vasodilation	
D. Morley, X.-Y. Zhang, A. A. Bove	294
Effects of the Mu-Selective Agonist, PL-017, on Brain Temperature, Oxygen Consumption and Heat Flux in the Rat	
C. M. Handler, E. B. Geller and M. W. Adler	295
Role of Opioids in Calcium and Calcitonin Gene-Related Peptide (CGRP)-Induced Hypothermia in Mice	
F. L. Smith, S. P. Welch and D. S. Dombrowski, W. L. Dewey	296

ORAL COMMUNICATIONS X

EPIDEMIOLOGY OF AIDS RISK BEHAVIORAL IN INTRAVENOUS DRUG ABUSERS

The Impact of HIV Testing on Risk for AIDS Behaviors	
D. S. Metzger, D. DePhilippis, P. Druley, C. P. O'Brien, A. T. McLellan, J. Williams, H. Navaline, S. Dyanick and G. E. Woody	297
Risk Reduction Through Indigenous Outreach to Intravenous Drug Users	
W. W. Wiebel, R. Booth, J. T. Brewster and S. Koester	299
AIDS Risk Patterns Among Los Angeles Drug Users	
M. D. Anglin, D. Longshore and J. Wang	300
Shooting Galleries in Alaska: Two Years Experience with AIDS Prevention Outreach Workers	
D. G. Fisher, D. L. Tarrant, C. Aiken, G. Perry-Crawford and P. Johnson	301
Low Rates of HIV Infection Among Substance Abusers Reporting High Risk Behavior: Trend or Time Bomb?	
G. A. Starch, L. B. Cottler, W. M. Compton, III, R. Price, R. Pearl and S. Keating	302
HIV Sero-Conversion and Treatment Status	
G. E. Woody, A. T. McLellan, C. P. O'Brien, J. Williams, H. Navaline, S. Dyanick, D. S. Metzger, D. DePhilippis and P. Druley	303
HIV Seropositivity and Effectiveness of Methadone Maintenance Treatment	
R. M. Swift, C. Love, R. Marlink and B. Foss	304
HIV Risk Status of New Methadone Admissions	
A. J. Saxon, D. A. Calsyn, E. A. Wells, T.R. Jackson, A. F. Wrede and J. Epps	305
Sexual Risk Behaviors Among Human Immunodeficiency Virus (HIV) Positive Patients at Methadone Clinics in New York City (NYC)	
A. F. Chu, T. Nemoto, K. Foster, L. S. Brown and D. Ajuluchukwu	306

ORAL COMMUNICATIONS XI

OPIOID ANTINOCICEPTION

Characterization of Antinociceptive Tolerance and Development of Physical Dependence to Morphine Using Continuous Intracerebroventricular Infusion in Mice
P. Horan and F. Porreca 307

Alterations in In Vivo Opioid Receptor Binding Following Arcuate Nucleus Syimulation in the Bat
M. H. Volk and E. A. Stein 308

Effect of Pertussis Toxin (PTX) on the Antinociceptive Profile of Buprenorphine (B) and Morphine (M): Evidence for Differential Regulation of Pain Transmission
H. Wheeler-Aceto and A. Cowan 309

Isobolographic Analysis of Interactions Between (μ) and (δ) Agonists in Rats: Potentiation Depend on μ Agonist and on Ratio of Compounds
J. U. Adams, R. J. Tallarida, E. B. Geller
and M. W. Adler 310

Efferent Projections of the Dorsal Raphe Nucleus and Nucleus Raphe Magnus
L. J. Sim and S. A. Joseph 311

Tramadol, an Atypical Opioid Analgesic: Opioid and Nonopioid Components
R. B. Raffa, E. Friderichs, W. Reimann, R. P. Shank
E. E. Codd, N. Selve, C. D. Connelly, R. P. Martinez
and J. L. Vaught 312

ORAL COMMUNICATIONS XII

MEDICAL AND PSYCHIATRIC FINDINGS AND CARE IN HIV-POSITIVE INTRAVENOUS DRUG USERS

Lack of Correlation Between Cellular Immunity and Delayed Hypersensitivity Reaction in Dually HIV and TB-Infected Drug Abusers
L. S. Brown, Jr., J. Bailey, A. L. Smith, T. Nemoto
and C. P. Felton 313

Long Latency AERPs in Drug Users With HIV Disease
T. B. Horvath, L. Handelsman and M. M. Schroeder . . . 314

Spect Regional Cerebral Blood Flow in HIV Infected Drug Abusers
C. H. van Dyck, S. W. Woods, S. S. O'Malley, B. L. Martini
C. J. McDougale, L. H. Price, J. H. Krystal, P. B. Hoffer
and T. R. Kosten 315

Peptide T Treatment of Cognitive Impairment HIV+ Intravenous Drug Users
M. I. Rosen, T. P. Bridge, S. S. O'Malley, H. R. Pearsall,
B. Martini, P. G. O'Connor, H. Brett-Smith, H. M. Thomas
C. VanDyck, S. W. Woods and T. R. Kosten 316

Drug and Sexual Behaviors Among Intravenous Drug Users (IVDUs) Who Were Enrolled in Isoniazid (INH) Therapy
T. Nemoto, L. S. Brown, Jr., M. M. Chu, A. F. Chu,
J. Bailey and D. C. Ajuluchukwu 317

Assessment of HIV Seroprevalence and Behavioral Risk Among Cocaine Users	
M. R. Kowalewski, H. K. Khalsa and M. D. Anglin	318
Psychiatric Disorders and Drug Use in 100 HIV-Infected IVDUs	
S. L. Batki, J. London, S. J. Ferrando, J. Pattillo, L. Manfredi, K. DeLucchi, C. Abbott and R. Hartwig . .	319
A Model Program for Primary Care of Intravenous Drug Users With HIV Infection	
P. G. O'Connor, S. Molde, S. Henry, W. L. Shockcor and R.S.Schottenfeld	320

ORAL COMMUNICATIONS XIII

ASSESSMENT AND NON-PHARMACOLOGICAL TREATMENT OF ADDICTIONS

The Myth of Polydrug Abuse Among Opiate Addicts in the U.S.	
J.C.Ball	321
Predictors of Relapse Levels in Cocaine and Methamphetamine Abusers	
F. G. Castro, E. H. Barrington, E. V. Sharp, and M. A. Walton	322
Inpatient vs. Outpatient Study: A Patient-Treatment Matching Design	
H. M. Pettinati, K. Meyers, B. D. Evans, J. M. Jensen F. N. Kaplan, C. R. Reutsch and J. I. Tracy	323
Arousal Responses to Cocaine Cues: Factors of Variance and Clinical Significance	
J. C. Negrete and S. G. Emil	324
Cue Reactivity in Heavy and Light Drinkers	
J. Greeley, W. Swift, J. Prescott and N. Heather . . .	325
Depression and Smoking Treatment: A Clinical Trial of an Affect Regulation Treatment	
S. M. Hall, R. Munoz and V. Reus	326
Increase in Current Perception Threshold After Cranial TENS	
D. Taylor and J. Katims	327
A Neurostimulator Device for Opiate Detoxification	
E. A. Elmoghazy, B. D. Johnson and F. A. Alling	328
Reduction of Tobacco Withdrawal Symptoms By Transcranial Electrostimulation Therapy (TCET)	
D. R. Jasinski, J.T. Sullivan, M. P. Testa and K. L. Preston	329

ORAL COMMUNICATIONS XIV

NEUROIMMUNOPHARMACOLOGY AND HIV PROLIFERATION

Delineation of Central Opioid Receptors Regulating Natural Killer Cell Activity In Vivo	
L. C. Band, A. Pert, W. Williams, M. Seggel, B. R. de Costa, D. Thomasson, K. C. Rice and R.J. Weber	330

The Effects of Dynorphin Peptides on Human Natural Killer Cell Activity In Vitro	
G. Bodner, S. Pinto, H. Albeck and M. J. Kreek	331
Morphine Causes the Selective Loss of CD4+/CD8+ Lymphocytes in the Murine Thymus Through the Induction of Apoptosis	
B. A. Fuchs and S. B. Pruetz	332
The Effect of Interferon-Alpha on Opioid Ligand Binding to Rat Brain Membranes	
R. A. Menzies, S. E. Rier, N. R. S. Hall and M. P. O'Grady	333
Morphine Attenuates IL-1 Levels in Transected Spinal Cord	
N. R. S. Hall, J. B. Gelderd, J. Oliver, S. Rier, M. P. O'Grady, R. A. Menzies, S. Filteau and T.A. Kaido	334
Interleukin-6 (IL-6) Reverses Morphine-Induced Suppression of the Antibody Response	
J. L. Bussiere, M. W. Adler, T. J. Rogers and T. K. Eisenstein	335
Morphine, Cytomegalovirus, and HIV-1 Growth	
C. C. Chao, G. Gekker, H. H. Balfour, Jr. and P. K. Peterson	336
Detection of HIV in CNS Tissue and Cells and Effects of Cocaine and Metabolites, In Vitro	
P. Shapshak, D. C. Mash, W. L. Hearn, M. Yoshioka, J. C. Arguello, B. J. Page, M. A. Fletcher, S. Nelson and L.Tate	337

ORAL COMMUNICATIONS XV

INTERRELATIONSHIPS BETWEEN COCAINE, DOPAMINE AND OPIATES

Preliminary Evidence that GBR12909 is Less Effective at Elevating Mesolimbic Dopamine Function than Cocaine	
R. B. Rothman, A. Kim, N. Greig, B. R. de Costa, K. C. Rice, F. I. Carroll and A. Pert	338
Effects of Intra-A10 Administration of the Dopamine D2 Agonist Quinpirole on Psychostimulant-Induced Motor Activity	
J. D. Steketee and P. W. Kalivas	339
Differential Effects of Cocaine and Dopaminergic Agonists on Hypokinesia Induced by Dopaminergic Antagonists	
P. Terry and E. Tirelli	340
Behavioral Hypersensitivity to Apomorphine Upon Acute Cocaine Withdrawal in Mice	
E. Tirelli and J. M. Witkin	341
Classically Conditioned Rotation: Tests with Cocaine and L-DOPA	
P. B. Silverman	342
Blockade of the Locomotor Stimulant Effects of Cocaine by Potential Antipsychotic Agents Active at Sigma Binding Sites	
J. M. Witkin, M. Menkel, P. Terry, M. Pontecorvo and J.L.Katz	343

Regulation of Mu-Opioid Receptors Repeated Following Exposure to Cocaine	
Y. Itzhak, I. Stein and D. C. Mash	344
Behavioral and Respiratory Effects of Buprenorphine in Monkeys	
J. Willetts, J Bergman, R. Brandsaard. M. Hampsch and W. H. Morse	345
The Effects of Nalbuphine on Cocaine- and Food-Maintained Responding in Rhesus Monkeys	
J. B. Kamien and N. K. Mello	346
Actions of (+)-Buprenorphine on Cocaine and Opiate-Mediated Effects	
N. A. Grayson, J. M. Witkin. J. L. Katz, A. Cowan and K.C.Rice	347
Chronic Buprenorphine Attenuates Cocaine Place Preference	
T. A. Kosten, D. W. Marby and E. J. Nestler	348

ORAL COMMUNICATIONS XVI

MEDICINAL CHEMISTRY - NOVEL COMPOUNDS

Epimeric Oxide Bridged 5-(<i>m</i>-hydroxyphenyl) Morphans as Probes for Narcotic Receptor-Mediated Phenomena	
D. Tadic, J. T. M. Linders, S. Mirsadeghi, R. B. Rothman, H. Xu, A. E. Jacobson and K. C. Rice	349
Computer-Assisted Molecular Modeling of Phenylmorphans	
J. T. M. Linders, A. E. Jacobson and K. C. Rice	350
Structural and Electronic Requirements for Binding at the Mu-Opioid Receptor in the Fentanyl Class of Compounds	
C. Cometta-Morini, P. A. Maguire and G. H. Loew	351
Mechanistic QSAR of μ-Selective Cyclic Opioid Peptides	
H. O. Villar, C. Chew and G. H. Loew	352
Synthesis and Evaluation of Conformationally Unrestricted Ethylenediamine Derivatives as Sigma Receptor Ligands	
L. A. Radesca, W. D. Bowen, L. J. DiPaolo, and B.R.deCosta	353
The Agonist Pharmacophore of the Benzodiazepine Receptor. Synthesis of a Selective Anticonvulsant/Anxiolytic	
H. Diaz-Arauzo, P. Skolnick and J. M. Cook	354
Small-Angle X-ray Diffraction Study of Interactions of Cannabinoids with Model and Biological Membranes	
D.-P. Yang, T. Mavromoustakos and A. Makriyannis	355
Interactions of Cannabinoids with Model and Biological Membranes Studied by Solid State 1H-NMR	
A. Makriyannis, D. P. Yang and T. Mavromoustakos	356

ORAL COMMUNICATIONS XVII

STUDIES ON PHARMACOLOGICAL TREATMENT OF OPIATE, COCAINE AND NICOTINE ADDICTIONS

Methadone Dosing Level: Effects on Treatment Outcome	
E. C. Strain, M. L. Stitzer, G. E. Bigelow and I. Liebson	357

A Repeated Treatment Design with Longitudinal Self-Report Data: Cumulative Versus Stabilizing Effects of Methadone Maintenance	
K. I. Powers and M.D. Anglin	358
Buprenorphine vs. Methadone for Opioid and Cocaine Dependence	
T. R. Kosten, R. S. Schottenfeld, C. H. Morgan, J. Falcioni and D. Ziedonis	359
Pilot Study with Low-Dose Buprenorphine	
P. Banyas, D. J. Tusel, H. W. Clark, K. Sees, L. Mongan, J. Nathan and E. Callaway	360
Assessment of Abuse Liability of Transnasal Butorphanol vs. Placebo in Treatment of Chronic Pain	
G. Gribkoff, G. Chu and R. E. Pyke	361
Fluoxetine and Behavioral Factors in Treatment of Cocaine Dependence	
J. Grabowski, R. Elk, K. Kirby, C. Cowan and H. Rhoades	362
Differential Effects of Serotonin Uptake Inhibitors on Addictive Behaviors in Alcoholics	
K. E. Kadlec and C. A. Naranjo	363
Waiting for Drug Treatment: A Naturalistic Study	
K. Holloway, L. Handelsman and M. Aronson	364
Depression as a Treatment Matching Factor in Cocaine Dependence Treatment	
D. Ziedonis and T. Kosten	365
Are all Placebos Created Equal? An Evaluation of Nicotine Polacrilex Placebo Doses	
S. J. Leischow, D. P. L. Sachs and N. L. Benowitz	366
Nicotine Transdermal Patch, Smoking Cessation, and Gender	
D. P. L. Sachs, U. Sawe and S. J. Leischow	367

POSTERS

MEDICINAL CHEMISTRY - NOVEL COMPOUNDS

The Combined Use of Molecular Mechanics and NMR Spectroscopy for the Conformational Analysis of U50488	
C. M. DiMeglio, M. Froimowitz, and A. Makriyannis	368
Synthesis of C-Ring-Substituted Etheno(Iso)Morphinans	
L. Maat and R. H. Woudenberg	369
An Efficient Synthesis of the 'ortho and para A-Isomer' of Oxide-Bridged 5-(3-Hydroxyphenyl)-2-methylmorphin	
K. Yamada, A. E. Jacobson and K. C. Rice	370

BIOCHEMICAL AND PHYSIOLOGICAL PHARMACOLOGY

The Modulatory Roles of Spinal Corticotropin-Releasing Factor and Dynorphin A on Acute Morphine Tolerance	
Z.H. Song and A. E. Takemori	371

Regional Levels of Met-Enkephalin-Arg⁶-Phe⁷ in Rat Brain Following Chronic Cocaine Administration	
E. M. Unterwald, J. Home, F. Nyberg, L. Terenius and M. J. Kreek	372
Presynaptic Dopamine Efflux is Enhanced by 5-HT Receptor Activation in Medial Prefrontal Cortex of Freely Moving Rats	
J. Chen, W. Paredes, H. M. van Praag and E. L. Gardner	373
The Effects of Cocaine and Other Monoamine Uptake Inhibitors on Cultured Mesencephalic Dopamine Neurons	
B. A. Bennett and J. E. Clodfelter	374
Photoaffinity Labels for the Cannabinoid Receptor	
A. Charalambous, Y. Guo, D. R. Compton, B. R. Martin, D. Houston, A. C. Howlett, J. Shilftone, S. H. Burstein and A. Makriyannis	375
Alcohol's Effects on Estradiol and LH in Female Rhesus Monkeys	
J. M. Drieze, N. K. Mello, J. H. Mendelson and M. Kelly	376
Binding and Functional Responses of Different Chemical Families of μ-Opioid Agonists in SH-SY5Y Cells	
E.M. Costa and G.H. Loew	377
Affinity Labeling of Mu Opioid Receptors in Rat and Bovine Brain Membranes Using a 14β-Bromoacetamido Derivative of Morphine	
J. M. Bidlack, R. A. Kaplan, R. Subbramanian and A. Seyed-Mozaffari and S. Archer	378
EFFECTS OF OPIOIDS, STIMULANTS, AND RELATED DRUGS AND TREATMENT AGENTS	
A Study of Oligonucleotides for Use as Reagents in a Drugs-of-Abuse Immunoassay	
D. G. Deutsch and E. R. Tombler	379
Possible Role for Serotonin in Discriminative Stimulus Effects of the Kappa Opioid U50,488	
M. E. Bronson, K. Burchett, M. Picker and L. Dykstra	380
What is Learned in Conditioned Tolerance Experiments?	
V. W. Rees, J. D. Greely and R. F. Westbrook	381
Drug/Drug Discrimination Learning Within the Conditioned Taste Aversion Procedure	
M. A. Kautz, S. T. Smurthwaite and A. L. Riley	382
The Reinforcing Versus Other Pharmacologic Effects of Chronic Cocaine Administration on Serotonin Turnover in the Rat Brain	
S.I. Dworkin	303
Peripheral Corticosterone Increases in Male Rats During Repeated Infusions of Cocaine	
N. S. Pilotte and E. P. Kornak	304
Conadal Factors and Ethanol's Actions on Hepatic Drug Metabolism: Effects on Cytochrome P450 CYP 2C11	
T. Badger, M. Ronis, C. Valentine, C. Lumpkin, R. Hakakk, J. Huang and D. Irby	385

Alcohol Attenuates the E₂B Stimulated LH Surge in Ovariectomized Monkeys	
N. K. Mello, J. H. Mendelson, J. Drieze and M. Kelly	386
Pharmacological Evidence for More Than Two Benzodiazepine Receptor Types	
P. Maguire, M. F. Davies, H. Villar and G. Loew	387
Alteration of Barbiturate Dependence by Benzodiazepine Inverse Agonists	
G. J. Yutrzenska, T. Stone and S. Anderson	388
Pentobarbital-Like Discriminative Stimulus Effects of Direct GABA_A Agonists	
D. M. Grech and R. L. Balster	389
Further Evidence That Nicotine Exerts Discriminative Stimulus (DS) Control of Behavior in the Rat Via an Action at Select Central Nicotinic Acetyl-Cholinergic Receptors (n-AChR's)	
R. James, H. Villaneueva, J. Johnson, S. Arezo and J. A. Rosecrans	390
Physical Dependence Exhibited in Mice Continuously Exposed to 1,1,1-Trichloroethane	
E. B. Evans and R. L. Balster	391
Behavioral and Neurochemical Responses to 4-Methylaminorex; a New Stimulant of Abuse	
G. R. Hanson, M. Johnson, L. Bush C. Bunker and J.W. Gibb	392
Evaluation of the Reinforcing Effects of Mazindol in Baboons	
C. A. Sannerud and R. R. Griffiths	393
Ritanserlin, a New Therapeutic Approach for Drug Abuse	
T. Meert, G. Clincke, Y. Gelders and G. De Smedt	394
Pharmacogenetic Assessment of the Use of Carbamazepine for the Treatment of Cocaine Addiction and Toxicity	
R. J. Marley and S. R. Goldberg	395
PRECLINICAL BEHAVIORAL PHARMACOLOGY	
A Non-thermal Nociceptive Model in Dogs	
P. Lloyd and M. H. Ossipov	396
A Study of Opiate Abuse During Pregnancy Using a Rat Model	
J. E. Olley, G. K. L. Tiong and T. L. Pierce	397
RTI-4614: A Highly Selective Ligand for, and A Pseudo-Irreversible Inhibitor of, the Mu Opioid Receptor	
H. Xu, G. A. Brine, F. I. Carroll, A. E. Jacobson, K. C. Rice and R. B. Rothman	398
Naltrindole Retards Tolerance Development to Morphine-Induced Effects on EEG and EEG Power Spectra	
H. Stamidis and G. A. Young	399
Agonist-Antagonist Properties of Partial Mu Opioid Agonists in the Drug Discrimination Procedure: The Role of Training Dose	
S. R. Mattox, S. S. Negus, M. J. Picker and L. A. Dykstra	400

Determination of an Apparent Dissociation Constant for Buprenorphine In Vivo Relative to That of Morphine	
K. A. Freeman H. Wheeler-Aceto, A. Cowan and R. J. Tallarida	401
The Effect of Buprenorphine Alone and in Combination with Cocaine on Self-Stimulation Thresholds	
P. Z. Manderscheid, S. Panicker, and R. A. Frank	402
Chronic Administration of GBRL2909 Partially Attenuates Cocaine-Induced Locomotor Activity in Rats	
C. S. Aulakh, R. Kilbun. B. R. de Costa, K. C. Rice and R. B. Rothman	403
Neurobehavioral Consequences of Gestational Cocaine Exposure	
L. P. Spear, G. Goodwin, C. Heyser, C. A. Moody and L. Rajachandran	404
Non-specific Effects of Carbamazepine on Cocaine Self-Administration in Rats	
L. G. Sharpe. J. H. Jaffe. F. J. Nouvet and J.L. Katz	405
Discriminative Stimulus Properties of Cocaine: Effects of the Novel Dopamine Autoreceptor Antagonists (+)-AJ 76 and (+)-UH 232	
P. M. Callahan, M. F. Piercey and K. A. Cunningham	406
Interaction of the Discriminative Stimulus Properties of PCP and Delta-THC in Rats	
P. Doty, M. J. Picker and L. A. Dykstra	407
Nicotine and Age-Associated Decrease in the Tail-Flick Latency	
E. S. Onaivi. S. Payne, J.W. Brock, S. Farooqui and C. Prasad	408
Pharmacological Characteristics of NIH 10443, An Irreversible Opioid Receptor Antagonist, in the Mouse Tail-Withdrawal Assay	
S. D. Comer, T. F. Burke, J. H. Woods and J.W.Lewis	409
Effect of Mu, Delta and Kappa Opioid Agonists on Heroin-Maintained Responding in the Rat	
S. S. Negus, M. B. Weinger, S. J. Henrickson and G.F.Koob	410
Genetic Variation in Opiate Receptors and its Relationship to Opiate Self-Administration	
G. I. Elmer, J. O. Pieper, S. R. Goldberg and F.R. George	411
Behavioral Evidence for an Interaction Between 5-HT₃ Receptors and Opioid Systems	
G. A. Higgins and E. M. Sellers	412
CLINICAL BEHAVIORAL PHARMACOLOGY	
Development of Behavioral Procedures for the Repeated Assessment of Drug Effects	
T. H. Kelly, R. W. Foltin and M. W. Fischman	413
Psychomotor Functioning During Alcohol and Cocaine Withdrawal: A Comparative Analysis	
L. Bauer	414

"Crack smoke" on Demand	
R. W. Wood, J. F. Graefe, C. P. Fang, J. Shojaie . . .	415
Marijuana Smoking: Acute Effects on Aggressive, Escape and Point-Maintained Responding	
D. R. Cherek, R. Spiga, R. H. Bennett and K. A. Cowan	416
Behavioral Economics of Drug Self-Administration: Effects of Enriched vs. Impoverished Environments on Human Drug Consumption	
W. K. Bickel, R. J. Degrandpre, S. T. Higgins and J. R. Hughes	417
Cardiovascular Reactivity and Risk for Substance Abuse Disorders	
R. E. Tarter, M. Kabene and H. B. Moss	418
Endogenous Vasopressin (AVP) and Intranasal Des-glycinamide AVP (DG-AVP) in Nicotine Craving	
M. J. Kelley and S. Lightman	419
Effects of Ethanol on Human Cooperative Responding	
R. Spiga, D. R. Cherek, J. Grabowski, R. H. Bennett and K. A. Cowan	420
An Assessment of the Potential Reinforcing Value of Privileges In a Methadone Maintenance Program	
J. M. Schmitz and J. Grabowski	421
Antagonist Sensitivity Time Course in Humans: Effects of Morphine-Naloxone Interval	
H.L. June, M. L. Stitzer and I. A. Liebson.....	422
CLINICAL PHARMACOLOGY	
Stability of Immunologic Markers During Acute Cocaine Withdrawal	
J. T. Christmas, S. Ruddy, J. S. Knisely and S. H. Schnoll	423
A Comprehensive Postmarketing Surveillance (PMS) Method for Assessing the Abuse Potential and Dependence Liability of Psychotropic Drugs	
C. A. Naranjo, U. Busto and K. L. Lanctot	424
Spontaneous EEG Changes During Tobacco Abstinence are Reversed by Caffeine	
C. Cohen, W. B. Pickworth, E. B. Bunker and J. E. Henningfield	425
Tramadol Hydrochloride Revisited-Analgesic Efficacy in Post-operative Pain	
A. Sunshine and F. L. Minn	426
Effects of Commonly Abused Drugs on Dynamic Pupilometry, Subjective and Physiologic Measures	
W. B. Pickworth, E. B. Bunker and J. E. Henningfield .	427
A Human Model for Studying Drug-Induced Concomitant Variations in Alcohol Consumption and Desire to Drink	
C. X. Poulos. C. A. Naranjo and K. E. Kadlec	428

The Fast Action Pharmacodynamics of Marijuana Smoking M. Huestis, A. Sampson, B. Holicky, J. Henningfield and E.Cone	429
Vagal Tone and Attention in 8-to 12-year Old Males Exposed to Opiates In Utero: A Preliminary Report J. E. Hickey, P. E. Seuss, L. Spurgeon, D. B. Newlin and S. W. Porges	430
Medical Care of HIV Disease in Methadone Maintenance Treatment E. Goosby, S. L. Batki, J. London, S. J. Ferrando C. Ryan, R. Hartwig and C. Abbott	431
NIDA Announces New Opiate/Stimulant Drug Testing Program for Medications Development A. A. Reid, L. R. Toll, I. Berzetei-Gurske, W. E. Polgar S. R. Brandt and G. T. Pryor	432
NIDA Launches a New Structure-Activity Database for Medications Development G. Barnett, G. Daly, K. Groover, M. McLoudrey and A.A. Reid	433
Tracing the Bridges: Social Network Characteristics and Risk Behavioral Among Drug Abusers and Their Significant Others R. K. Price, L. B. Cottler, D. Mager and S. Keating . .	434
Healthstreet: Linking Drug-Abuse Treatment, AIDS Prevention, and Other Public Health Services in St. Louis D. J. Claverie, L. B. Cottler, R. K. Price and W. M. Compton, III, W.L. Dotson and D. Sharma	435
Risk Behavior Relationships Among Heterosexual Injection Drug Users R. Booth and J. T. Brewster	436
Assessment of Knowledge of AIDS and Risk Behaviors Among Injecting Drug Users (IDUs) V. A. Gonzalez, N. Siddiqui, L. S. Brown, Jr., C. Y. Veloz, J. Mantell, and A. Hernandez	437
HIV Risk Behavior in Drug Users: increased Blood "Booting" During Cocaine Injection L. Greenfield, G. E. Bigelow and R. K. Brooner	438
DIAGNOSIS, ASSESSMENT AND SYMPTOMATOLOGY	
Patterns of Use Among Cocaine Users F. R. Levin, J. Hess, D. Gorelick and P. J. Fudala . .	439
Changes in Clinical Status of Newly Abstinent Hospitalized Cocaine Users R. Cambor, A. Ho, G. Bodner, S. Lampert, J. Kennedy and M. J. Kreek	440
Intensity of Craving is Independent of Depression in Newly Abstinent Chronic Cocaine Users A. Ho, R. Cambor, G. Bodner and M. J. Kreek	441
Subjective Symptoms of Cocaine Withdrawal F. Gawin, H. K. Khalsa and M. D. Anglin	442

The Urinary Excretion of Benzoylcegonine: Implications for a Multi-Compartment Model of Cocaine Pharmacokinetics H. R.-Kranzler, S. S. Dellafera, L. D. McLaughlin and S. H. Y. Wong	443
The Psychopathy Checklist with Women Addicts M. J. Rutherford, J. S. Cacciola and A. I. Alterman . .	444
Psychiatric Disorders in Addicted Women J. S. Knisely, D. L. Haller and S. H. Schnoll	445
Gender Differences in the Antisocial Behavior of Intravenous Drug Abusers L. J. Felch, R. K. Brooner and G. E. Bigelow	446
Personality Correlates of Drug Abusers With and Without Depressive Disorders E. E. Rouşar, III, R. K. Brooner, P. T. Costa, M. W. Regier, J. Herbst and C. W. Schmidt	447
The Difficulties and Implications of Distinguishing Primary and Secondary Drug Abuse W. M. Compton, III, L. B. Cottler and J. Hudziak . . .	448
A Preliminary Evaluation of the Personality Traits in a Population of Drug Dependent Professionals USING the Tridimensional Personality Questionnaire (TPQ) J. Rosecrans, J. Lancaster, M. Basel, B. Lemmond and J. Knisely	449
Validity of Patients' Self-Reported Drug Use at Treatment Intake M. F. Sherman and G. E. Bigelow	450
Topographic Quantitative EEG Findings in Subjects with 15+ Years of Cumulative Daily THC Exposure F. Struve, J. Straumanis, G. Patrick, G. Norris, J. Leavitt and P. Webb	451
Differences in Complex Reaction Time Between THC Users and Non-user Controls J. Leavitt, P. Webb, G. Norris, F. Struve, J. Straumanis, G. Patrick, M. Fitz-Gerald and F. Nixon	452
PHARMACOLOGICAL TREATMENT	
Joint Action of Methadone Dose and Take Home Dose Frequency in Treatment Compliance H. Rhoades, R. Elk, K. Kirby, K. Cowan and J. Grabowski	453
The Effect of Bate of Methadone Metabolism on Treatment Outcome Study One: Methadone Metabolism and Craving, Withdrawal, and Dysphoria D. Tusel, P. Banys, K. Sees, P. Reilly and K. Delucchi	454
Approach to Management of Methadone Patients Using Illicit Drugs D. R. Tiuseco and R. I. H. Wang	455

Preliminary Data From a Comparison of Three Levels of Methadone Services	
D. A. Calsyn, E. A. Wells, T. R. Jackson, A. J. Saxon and A. F. Wrede	456
Cannabis Use and its Relationship to Other Drug Use Among Patients in a Methadone Maintenance Program	
T. D. Nirenberg, R. Swift, A. Sirota, P. B. DePetrillo, M. R. Liepman and A. A. Wartenberg	457
Naltrexone in the Treatment of Federal Probationers	
J. Tilly, C. P. O'Brien, A. T. McLellan, G. E. Woody, D. S. Metzger and J. Cornish	450
Regional Cerebral Blood Flow (rCBF) Changes in Naltrexone Precipitated Withdrawal from Buprenorphine	
H. M. Thomas, C. H. van Dyck, M. I. Rosen, M. E. Waugh, P. G. O'Connor, H. R. Pearsall, P. B. Hoffer, S. W. Woods and T. R. Kosten	459
Buprenorphine's Effects on Morphine and Cocaine Challenges in Heroin and Cocaine Dependent Men	
S. K. Teoh, P. Sintavanarong, J. Kuehnle, J. H. Mendelson, E. Hallgring, E. Rhoades and N. K. Mello	460
Preliminary Results of An Open Trial of Buprenorphine in the Outpatient Treatment of Combined Heroin and Cocaine Dependence	
D. R. Gastfriend, J. H. Mendelson, N. K. Mello and S.K. Teoh	461
EEG Sleep Architecture in Cocaine- and Heroin-Dependent Subjects During Buprenorphine Maintenance	
S. E. Lukas, C. M. Dorsey, A. Abdulali, M. Fortin, S. Abdulali, J. H. Mendelson, N. K. Mello and S. Cunningham	462
Pre- and Post-Treatment Cue-Reactivity in Cocaine Addicts Treated with Bupropion	
A. Margolin, S. K. Avants, D. Ziedonis, I. Petrakis, and T. R. Kosten	463
Bromocriptine: Anti-craving and Other Effects in Patients Abusing Cocaine	
R. I. H. Wang, J.-K. Cho, B. Roh and D. Salstrom	464
Effects of Cocaine Alone and in Combination with Mazindol in Human Cocaine Abusers	
K. L. Preston, J. T. Sullivan, G. E. Bigelow, P. Berger and F. J. Vocci	465
Cocaine Blocking Effects of Ondansetron	
J. T. Sullivan, D. R. Jasinski, K. L. Preston, M. Testa and J. M. Bell	466
Quantitative Magnetic Resonance Imaging in Opioid- and Cocaine-Dependent Men	
L. Amass, R. Nardin, J. H. Mendelson, S. K. Teoh and B. T. Woods	467
Bupropion in the Treatment of Primary Alcoholism	
M. Ionescu-Pioggia, B. Powell, B. Samara, B. Liskow, J. Campbell, J. Ascher, A. Johnston and J. Nickel	468

Serotonergic Agents Modulate Weight Gain Following Smoking Cessation	
O. F. Pomerleau, B. Spring and C. S. Pomerleau	469
Nicotine Patch: Effect on Spontaneous Smoking	
E. B. Bunker, W. B. Pickworth and J. E. Henningfield	470
EEC Sleep Disturbances in the Elderly and the Use of Passive Body Heating as a Non-pharmacologic Method for Improving Sleep	
C. M. Dorsey, S. E. Lukas, A. Satlin, S. Cunningham and A. Abdulali	471

PSYCHOLOGICAL AND SOCIAL TREATMENTS

Comparing Family Loss In Opiate Abusers and Other Drug Abusers: Treatment Implications	
S. A. Tiegel, J. L. Johnson and D. R. McDuff	472
Methadone Maintenance Outcome: Bole of Detox Fear and Its Treatment	
J. B. Milby, M. Gentile, M. K. Sims., N. Haas, N. Huggins, A. Hohmann, A. T. McLellan and G. Woody	473
Contingency Management Aftercare for Polydrug Abuse of Methadone Maintenance Patients	
K. C. Kirby, M. L. Stitzer and M. Brackish	474
Cocaine Abuse: A Comparative Evaluation of Therapeutic Modalities	
H. K. Khalsa, M. D. Anglin, A. Paredes, P. Potepan and C. Potter	475
Predicting Completion of Outpatient Cocaine Treatment	
E. A. Wells, R. Gainey, J. D. Hawkins and R. F. Catalano	476
Effect of Methadone Dose Contingency Treatment on Cocaine Abuse in a Methadone Program	
S. M. Stine, M. Freeman, B. Burns, and T. R. Kosten	477
Effects of Cocaine and Alcohol, Alone and in Combination, on Human Learning and Performance	
S. T. Higgins, C. R. Rush, J. R. Hughes, W. K. Bickel, M. Lynn and M. A. Capeless	478
Contingent Reinforcement of Abstinence with Individuals Abusing Cocaine and Marijuana	
A. J. Budney, S. T. Higgins, D. D. Delaney, L. M. Kent and W. K. Bickel	479

EPIDEMIOLOGY AND PUBLIC POLICY

Natural History of Cocaine Abuse: From First Cocaine Use To Two Years After Treatment	
A. Paredes, H. K. Khalsa, M. D. Anglin, P. Potepan and C. Potter	480
Characteristics of Applicants to a Cocaine Research Program	
E. Cornell, L. Butler-Weyher, R. W. Foltin and M. W. Fischman	481
Legal Needle Buying in Lieu of Needle Exchange?	
W. M. Compton, III and L. B. Cottler	482

Post-Traumatic Stress Disorder Among Substance Users From the General Population	
D. Mager, A. Janca, W. M. Compton, III, E. Spitznagel, and L. B. Cottler	483
The Relationship Between Substance Use and Area of Practice Among Registered Nurses	
A. M. Trinkoff	484
Factors That Influence Physicans' Prescribing of Benzodiazepines	
P. K. Horvatic, R. Poses and S. H. Schnoll	485
A Survey of Current and Proposed Drug Testing Policies for Faculty, Employees and Students at U.S. Colleges and Universities	
P. J. Fudala, L. Fields, N. A. Kreiter and W. R. Lange	486
Prevalence of Hepatitis C in Substance Abusers	
M. Fingerhood, J. Sullivan and D. Jasinski	487
The Increasing Need for Primary Health Care as an Integral Treatment Component	
K. Foster, A. Chu, D. Ajuluchukwu and L. S. Brown	488
Toxicology Screens for Cocaethylene in Emergency Department and Trauma Admissions Associated with Cocaine Intoxication	
D. C. Mash, D. C. Tanis, K. S. Schrank, J. S. Augenstein, S. Rose, W. L. Hearn, M.C. Gavancho-Sotomayor and F. W. Stitt	489
ANNUAL REPORTS	
Biological Evaluation of Compounds for Their Physical Dependence Potential and Abuse Liability. XIV. Animal Testing Committee of the Committee on Problems of Drug Dependence, Inc. (1991)	
A. E. Jacobson	490
Dependence Studies of New Compounds in the Rhesus Monkey and Mouse (1991)	
M. D. Aceto, E. R. Bowman, L. S. Harris and E. L. May	513
Evaluation of New Compounds for Opioid Activity (1991)	
J. H. Woods, F. Medzihradsky, C. D. Smith, G. D. Winger and C. P. France	559
Progress Report from the Testing Program for Stimulant and Depressant Drugs (1990)	
G. A. Patrick, L. S. Harris, M. A. Nader, W. L. Woolverton, G. Winger and J. H. Woods	604
Progress Report from the Testing Program for Stimulant and Depressant Drugs (1991)	
G. Winger, J. H. Woods, G. A. Patrick, L. J. Powell, L. S. Harris, M. A. Nader and W. L. Woolverton	624
Subject Index	640
Author Index	669
NIDA Monographs	685